Active substance
Results for the substance apixaban
20 results
About this active substance
Apixaban is an oral anticoagulant from the class of direct factor Xa inhibitors, used for the prevention and treatment of thromboembolic disorders. It is indicated for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, as well as for the prevention and treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE).
Apixaban works by inhibiting factor Xa, an essential enzyme in the coagulation process, thereby reducing the formation of blood clots. Unlike traditional anticoagulants such as warfarin, apixaban does not require regular INR (prothrombin time) monitoring and has fewer drug interactions.
Common side effects include minor bleeding, such as nosebleeds (epistaxis) or bruising. In rare cases, severe bleeding, such as gastrointestinal or intracranial hemorrhage, may occur. Patients should inform their doctor about any signs of unusual bleeding.
Apixaban should be used with caution in patients with severe renal impairment, liver disease, or an increased risk of bleeding. It is contraindicated in patients with active bleeding or those undergoing treatments that significantly increase the risk of hemorrhage.
Apixaban works by inhibiting factor Xa, an essential enzyme in the coagulation process, thereby reducing the formation of blood clots. Unlike traditional anticoagulants such as warfarin, apixaban does not require regular INR (prothrombin time) monitoring and has fewer drug interactions.
Common side effects include minor bleeding, such as nosebleeds (epistaxis) or bruising. In rare cases, severe bleeding, such as gastrointestinal or intracranial hemorrhage, may occur. Patients should inform their doctor about any signs of unusual bleeding.
Apixaban should be used with caution in patients with severe renal impairment, liver disease, or an increased risk of bleeding. It is contraindicated in patients with active bleeding or those undergoing treatments that significantly increase the risk of hemorrhage.
-
-
ELIQUIS 2.5mg film-coated tablets BRISTOL MYERS SQUIBB ORIGINAL MEDICINE
-
APIXABAN PHARMAZAC 2.5mg film-coated tablets
-
APIXABAN PHARMAZAC 5mg film-coated tablets
-
APIXABAN BIOEEL 2.5mg film-coated tablets
-
APIXABAN BIOEEL 5mg film-coated tablets
-
APIXABAN SLAVIA 2.5mg film-coated tablets SLAVIA PHARM
-
APIXABAN SLAVIA 5mg film-coated tablets SLAVIA PHARM
-
LYXARO 2.5mg film-coated tablets ANTIBIOTICE
-
LYXARO 5mg film-coated tablets ANTIBIOTICE
-
APIXABAN TOWA PHARMACEUTICAL EUROPE 2.5mg film-coated tablets
-
APIXABAN TOWA PHARMACEUTICAL EUROPE 5mg film-coated tablets
-
APIXABAN GRINDEKS 2.5mg film-coated tablets AS GRINDEKS
-
APIXABAN GRINDEKS 5mg film-coated tablets AS GRINDEKS
-
APIXABAN VIATRIS PHARMA 2.5mg film-coated tablets VIATRIS LIMITED
-
APIXABAN VIATRIS PHARMA 5mg film-coated tablets VIATRIS LIMITED
-
FYDOCO 2.5mg film-coated tablets VIATRIS LIMITED
-
FYDOCO 5mg film-coated tablets VIATRIS LIMITED
-
APIXABAN TEVA 2.5mg film-coated tablets
-
APIXABAN TEVA 5mg film-coated tablets